$Tesla Motors(TSLA)$ 's stock price surged 12% to $162.13 on Wednesday, a day after the company reported its sharpest revenue drop in 12 years, a 55% drop in net profit from a year earlier.All key indicators missed expectations, but they announced a budget car plan! Wall Street analysts had mixed reactions. Here are the latest analyst views and comments on Tesla stock:1.Bank of America: More Positive Catalysts Ahead $Bank of America(BAC)$ analysts upgraded their rating on Tesla from "neutral" to "buy," but maintained a target price of $220. They cited the company's management addressing recent negative catalysts like slowing sales growth, narrowing margins, product launch concerns, layoffs, and high invent

This year, the energy sector in the US stock market has outperformed the $S&P 500(.SPX)$ , and the price of crude oil has been on a tear. The WTI crude oil futures have jumped over 35% in the past three years, fueling a significant increase in free cash flow for US oil stocks. As profits rise, so do stock prices!Here are five US oil stocks that have the highest correlation with $WTI Crude Oil - main 2406(CLmain)$ prices and are also rated as "buy" by Bank of America.1.Targa Resources Corp Analysts predict that $Targa Resources(TRGP)$ will benefit from overbuilding in the Permian Basin's natural gas liquids pipeline system, and the company still expects pr

$Medtronic PLC(MDT)$ is a medical device stock that covers over 150 countries and sells products for over 70 different diseases. It's truly a core holding for healthcare investors. But the stock has been in a slump, with its share price falling 8% over the past five years.Now, investors in Medtronic are faced with a choice: buy, sell, or hold?Can MDT regain its growth?One of the reasons this medical device stock has been languishing is its lackluster growth in recent years. Over the past five years,, Medtronic's average quarterly revenue growth has been less than 2%, which is difficult to attract growth-oriented investors. But Medtronic's future revenue growth can still be expected to accelerate. The company is actively developing innovative new pr

图片$S&P 500(.SPX)$ closed down 62 points, or 1.2%, on Monday, marking its steepest two-day percentage decline in over a year and its largest two-day point decline since late 2022. But market analysts generally believe the US stock market hasn't fallen to the bottom！Recently, the US stock market has been buffeted by two major forces: the Fed's expectations for interest rate cuts and the situation in the Middle East.Nicholas Rabe, co-founder of DataTrek, said:The stock market is now caught between a rock and a hard place. On one hand, there's a robust and inflationary US economy, and on the other, there's a widening conflict in the Middle East that's setting the stage for an economic recession. Plus, the so-called 'fear index' –

图片Pharmaceutical giant $Merck(MRK)$ has acquired startup Abceutics for $208 million, acquiring the company's medical technology payloads in combination with selective enhancers (PBSEs) that have high potential in the field of antibody-drug conjugate(ADC).ADC drugs are currently a hot area of oncology drug development, and many large pharmaceutical companies want to get a piece of the pie, and Merck is no exception.Merck has six ADC drugs in late-stage clinical trials for cancers including small cell lung cancer, non-small cell lung cancer (NSCLC) and endometrial cancer. Mordor Intelligence predicts the global ADC drug market will grow from $12 billion this year to $44 billion in 2029.In the last 12 months, Merck's revenue was just over $60 billion.

图片With the Fed expected to cut rates, high-yield dividend stocks are poised for a major rally. Fund managers are eager to snap up these juicy dividends in a low-rate environment. $AT&T Inc(T)$ , the telecom giant, and $Pfizer(PFE)$ , the drugmaker, seem like steals right now. Both of these stocks offer yields above 6%. Once rates start to drop, fund managers will be all over them like flies on honey!1.AT&T AT&T, a household name in the US telecom industry, is trading at a significant discount. While the industry average trailing PE ratio is 11.7, AT&T's PE ratio stands at just 8.84.This low valuation, coupled with AT&T's impressive 6.4% annualized yield, makes it a potential gem for both

图片The earnings season is coming, and it could be just the catalyst needed to take the US stock market to the next level!This week, companies like $Delta Air Lines(DAL)$ , $Canopy Growth Corporation(CGC)$ , $JPMorgan Chase(JPM)$ , and $Fastenal(FAST)$ are all set to release their first-quarter earnings, and chances are they'll beat analysts' expectations.Chris Senyek, the chief investment strategist at Wolfe Research, said:Over the past four quarters, the S&P 500 has beaten earnings estimates by an average of 7.1%. And since analysts have already trimmed their first-quarter forecasts by 2.5%, it's likely we'll see some p

图片Guess which stock is the cheapest among the tech "Magnificent Seven"? The answer is $Apple(AAPL)$ !Here's why Apple's stock is relatively cheaper compared to its top tech peers.Apple's Discounted ValuationFor younger, unprofitable companies, the price-to-sales ratio might be a good indicator to assess stocks and their correlation with revenue. But for more mature, industry-leading companies, the price-to-earnings ratio is probably a better metric. So, combining P/E with P/FCF ratio gives a more accurate picture of the company's valuation.Not long ago, $Alphabet(GOOG)$ $Alphabet(GOOGL)$ was the cheapest stock among the "Magnificent Seven". But its share price h

Finally, the US stock market has taken a tumble. This drop was led by the previously rallying AI stocks. In fact, $NVIDIA Corp(NVDA)$ was stalling a bit when it hit the $1000 mark, and $Advanced Micro Devices(AMD)$ took a big tumble, falling over 8%.Meanwhile, gold has hit a record high. Logically speaking, with the Fed's expectation of a rate cut slipping, gold's rise seems a bit odd. Maybe it's a sign of market fear, with investors seeking safe havens.1.Look for the bad news after the crashOn the news side, the March ISM non-manufacturing PMI in the US was lower than expected, while the previously released manufacturing PMI exceeded expectations and entered the expansion zone for the first time. Theoreti

图片Biotech is one of the most innovative industries out there. From 2012 to 2022, thanks to the innovation boom like the Human Genome Project and ultra-low interest rates, biotech stocks have significantly outperformed $S&P 500(.SPX)$ . And now, with interest rate cuts looming, biotech stocks and ETFs are poised for an unmissable investment opportunity.According to Grand View Research, the global biotech market will grow to $3.88 trillion at a compound annual growth rate (CAGR) of 13.96% during the period 2024-2030. In addition, Verified Market Research expects the size of the global biotech market to exceed $5.25 trillion by 2030. As for the nano-medicine segment, Precendence Research forecasts it'll grow to $183.11 billion with an 8.13% CAGR

图片Recently, $UnitedHealth(UNH)$ 's stock price has been shaking and dropping from its 52-week high. However, looking at the bigger picture, the "danger" UnitedHealth is facing right now could very well be an "opportunity" for investors.A key player in the US healthcare systemAs the largest health insurance company in the US, it provides medical services to 152 million people and has expanded its business from insurance to include healthcare services and technology systems.UnitedHealth is deeply integrated into the US healthcare system, which serves as its strong moat. Long-term investors do not need to react to the recent cyber attack incident.Don’t let down investorsFinancially speaking, UnitedHealth is a stellar company with annual revenue exceed

图片You might know“Magnificent Seven”, the tech titans in the US stock market, and these seven healthcare stocks definitely share the following characteristics. They’re the leaders in their niches, have raked in obscene returns over the past decade, and their futures look as bright as a billion-dollar smile!1+2.Eli Lilly and Novo NordiskWhen it comes to $Eli Lilly(LLY)$ and $Novo-Nordisk A/S(NVO)$ , these two giants in the diabetes and obesity treatment market are all about “weight loss drugs.” And they’re both on track to becoming trillion-dollar stocks in the next decade. Lilly’s Zepbound got approved last year, while Novo Nordisk’s Wegovy sales are skyrocketing, and they’ve even reported promising phase on

图片The AI craze is heating up and pushing US stocks to new highs, but some investors are starting to worry that a bubble might be forming. The skyrocketing valuations are making them nervous, especially considering the more than 25% surge in $S&P 500(.SPX)$ since late October.Economist David Rosenberg pointed out three glaring divergences in the stock market earlier this month, hinting at an inevitable pullback. Despite the strong performance of $DJIA(.DJI)$ and $S&P 500(.SPX)$ , the Dow Jones Transportation Average, a bellwether of economic health, is lagging. The HYG/TLT ratio is trending down, and even the tech sector is starting to show weakness.His US

图片You can snag these three healthcare stocks for less than a grand and set yourself up for future success!1.PfizerNow is the perfect time to grab $Pfizer(PFE)$ stock. With 19 launches in 18 months and a string of acquisitions, including cancer expert $Seagen(SGEN)$ , Pfizer is poised to enter a new era of revenue growth.The stock is trading at a forward P/E ratio of 12, which is a steal considering the company's long-term potential.2.CRISPR Therapeutics $CRISPR Therapeutics AG(CRSP)$ has bagged the world's first regulatory approval for a CRISPR-based gene editing product. The company's recently approved product, Casgevy, treats sickle cell disease and beta-thalass